About Smick Laboratories
Smick Laboratories is a company based in India. It operates as a B2B. Smick Laboratories operates in a competitive market with competitors including Unither, Akums, Jubilant Life Sciences, Recipharm and CoreRx, among others.
- Headquarter India
- SectorsHealthcare
- Website smicklabs.com
- Legal Name Smick Laboratories Private Limited
- Date of Incorporation 05 Aug, 2014
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹18.46 Cr
FY 2024 · +79% YoY
- Net Profit₹95 Lakh
FY 2024 · 5% margin
- EBITDA₹1.32 Cr
FY 2024 · 7% margin
Associated legal entities of Smick Laboratories
Smick Laboratories operates through Smick Laboratories Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Smick Laboratories Private Limited CIN U74120MH2014PTC256879 | Active | 05 Aug 2014 | Mumbai, Maharashtra | ₹18.5 Cr | – | 4 | View details |
Board of directors of Smick Laboratories Private Limited (Smick Laboratories)
Smick Laboratories Private Limited is the primary company behind Smick Laboratories. The board of Smick Laboratories Private Limited currently have 4 directors; the longest-serving is Ketan Dinesh Shah, appointed in 2014. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ketan Dinesh Shah DIN 06619636 | Director | 05 Aug 2014 | 12 yrs 2 mo | Smick Laboratories Private Limited |
| Mittal Ketan Shah DIN 06842249 | Director | 05 Aug 2014 | 12 yrs 2 mo | Smick Laboratories Private Limited |
| Ashish Kumar Jajodia DIN 00299794 | Director | 01 Jul 2016 | 10 yrs 3 mo | Smick Laboratories Private Limited |
| Manish Kumar Jajodia DIN 00299619 | Director | 01 Jul 2016 | 10 yrs 3 mo | Smick Laboratories Private Limited |
Financials of Smick Laboratories
Figures of Smick Laboratories Private Limited, the primary company behind Smick Laboratories, for FY 2024. Revenue was ₹18.46 Cr (+79% year on year). Net profit was ₹95 Lakh (5% margin). EBITDA was ₹1.32 Cr (7% margin). Revenue has grown at a compounded annual rate of +46% over three years and +9% over five years.
- ₹18.46 CrRevenue · FY 2024 · +79% YoY
- ₹95 LakhNet profit · 5% margin
- ₹1.32 CrEBITDA · 7% margin
- ₹2 LakhPaid-up capital
- +46%Revenue CAGR, 3 years
- +9%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Smick Laboratories Private Limited are on its company page.
Detailed financial statements for Smick Laboratories
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Smick Laboratories
Smick Laboratories operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Unither, Akums, Jubilant Life Sciences, Recipharm and CoreRx, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| unither-pharma.com | 1993 | Paris, France | – | – | Contract development and manufacturing organization for proprietary and generic drugs | |
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| jubl.com | 1978 | Noida, India | – | – | Company offering a suite of R&D and manufacturing services for small molecules and generics | |
| recipharm.com | 1995 | Jordbro, Sweden | – | 1,083 | Pharmaceutical development and manufacturing services are offered contractually. | |
| corerxpharma.com | 2006 | Clearwater, United States | $15M | – | CDMO with a focus on early phase drug product development | |
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. | |
| windlas.com | 2001 | Gurugram, India | $12.96M | 1,264 | Biopharma regulatory affairs, quality control, and strategy services are provided. | |
| medpharm.com | 1998 | Guildford, United Kingdom | – | 108 | Topical and inhaled drug delivery formulations are developed and manufactured. |
Detailed competitors of Smick Laboratories
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Smick Laboratories
10 companies that operate in the same segment as Smick Laboratories (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Smick Laboratories
Smick Laboratories is headquartered in India.
The primary company behind Smick Laboratories, Smick Laboratories Private Limited, reported revenue of ₹18.46 Cr for FY 2024, up 79% year on year.
Smick Laboratories manufactures and supplies apis, excipients, and finished dosage forms to various companies through providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and api and excipients. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field.
Smick Laboratories's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Smick Laboratories operates through Smick Laboratories Private Limited.
The legal entities of Smick Laboratories currently have 4 directors, including Ashish Kumar Jajodia, Ketan Dinesh Shah, Manish Kumar Jajodia and others.